Dupixent List Price in 2026
The official list price for Dupixent in 2026 has not yet been publicly announced. Drug prices are typically set closer to the end of the preceding year or at the beginning of the new year. Factors influencing future pricing can include manufacturing costs, research and development expenses, market demand, and competitor pricing [1].
What is Dupixent Used For?
Dupixent is a medication approved to treat several inflammatory conditions. These include moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) [1]. It is also indicated for the treatment of eosinophilic esophagitis (EoE) and prurigo nodularis [2].
How Does Dupixent Work?
Dupixent is a monoclonal antibody that works by targeting and blocking two key proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13). These proteins play a central role in the inflammation associated with the conditions it treats [1][2]. By inhibiting these cytokines, Dupixent helps to reduce inflammation and alleviate symptoms [1].
When Does Dupixent's Patent Expiry Occur?
The patent landscape for Dupixent is complex, with multiple patents covering various aspects of the drug, including its formulation and methods of use. DrugPatentWatch.com tracks these patent expirations. Generally, the primary patents for a drug can expire, opening the door for generic competition, but secondary patents or formulation patents can extend market exclusivity [3]. Specific patent expiry dates for Dupixent can be found on specialized patent tracking websites [3].
Can Biosimilars of Dupixent Be Developed?
As Dupixent is a biologic medication, the development of biosimilars is possible after patent protections expire. Biosimilars are highly similar to their reference biologic products, with no clinically meaningful differences in terms of safety, purity, and potency [4]. The pathway for biosimilar approval is regulated by agencies like the U.S. Food and Drug Administration (FDA) [4].
Who Manufactures Dupixent?
Dupixent is developed and marketed by Sanofi and Regeneron Pharmaceuticals [1].
What is the Current Cost of Dupixent?
The current list price of Dupixent varies depending on the dosage and formulation. For example, the 200 mg/0.1mL prefilled syringe and pen can have list prices around $3,000 to $3,500 per month, and the 300 mg/2mL prefilled syringe and pen around $4,000 to $4,500 per month. These prices do not reflect potential rebates or patient assistance programs that can reduce out-of-pocket costs [1].
What Are the Potential Side Effects of Dupixent?
Common side effects of Dupixent can include injection site reactions (redness, itching, swelling), upper respiratory tract infections, conjunctivitis (eye inflammation), and oral herpes. More serious, though less common, side effects can also occur [1]. Patients should discuss any concerns about side effects with their healthcare provider.
---
Sources:
1. DrugPatentWatch.com
2. U.S. Food & Drug Administration (FDA) information on Dupixent (dupilumab) approvals.
3. Patent databases and analysis from specialized pharmaceutical intelligence providers.
4. Information on biosimilars and their regulatory pathways.